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Abstract
Background: Calcitonin gene-related peptide (CGRP) is widely distributed in nociceptive pathways in human
peripheral and central nervous system and its receptors are also expressed in pain pathways. CGRP is involved in
migraine pathophysiology but its role in non-headache pain has not been clarified.
Methods: We performed a systematic literature search on PubMed, Embase and ClinicalTrials.gov for articles on CGRP
and non-headache pain covering human studies including experimental studies and randomized clinical trials.
Results: The literature search identified 375 citations of which 50 contained relevant original data. An association
between measured CGRP levels and somatic, visceral, neuropathic and inflammatory pain was found. In 13 out of 20
studies in somatic pain conditions, CGRP levels had a positive correlation with pain. Increased CGRP levels were
reported in plasma, synovial and cerebrospinal fluid in subjects with musculoskeletal pain. A randomized clinical trial on
monoclonal antibody, which selectively binds to and inhibits the activity of CGRP (galcanezumab) in patients with
osteoarthritis knee pain, failed to demonstrate improvement of pain compared with placebo. No studies to date have
investigated the efficacy of monoclonal antibodies against CGRP receptor in non-headache pain conditions.
Conclusion: The present review revealed the association between measured CGRP levels and somatic, visceral,
neuropathic and inflammatory pain. These data suggest that CGRP may act as a neuromodulator in non-headache
pain conditions. However, more studies are needed to fully understand the role of CGRP in nociceptive processing and
therapy of chronic pain.
Background
The mechanism of nociception is complex involving the
detection of a noxious event by nociceptors, and signal
processing in the peripheral and central nervous system
(CNS). Recent studies have identified specific substances
and receptors with potential roles in nociception that pro-
vide therapeutic targets, including substance P, CGRP, glu-
tamate, serotonin, TrkA receptor, vanilloid receptor and
NMDA receptor [1, 2]. Chronic pain resulting from disease
or injury is a major public health problem and a common
complaint in general population with a lifetime prevalence
ranging from 12 to 30% [3] and an enormous impact and
burden on society and individuals [4]. Despite tremendous
scientific effort over the past years, current pain manage-
ment treatment remains suboptimal [5]. There is an unmet
and urgent need for new effective therapeutic options for
the management of chronic pain. Migraine manifests as
pain with associated sensory disturbances and is consid-
ered as a chronic condition with episodic manifestations
[6]. The role of CGRP in migraine pathophysiology has
gained considerable interest in recent years [7, 8]. This led
to the development of small molecule CGRP receptor an-
tagonists for acute and preventive treatment of migraine
[9, 10] and monoclonal antibodies against CGRP mecha-
nisms for migraine prevention [11, 12].
CGRP is a 37-amino-acid neuropeptide identified in
1982 [13]. It belongs to a family of peptides including
adrenomedullin, amylin and calcitonin with diverse bio-
logical functions in the periphery and in the central ner-
vous system [14, 15]. To what extent CGRP is involved
in non-headache pain conditions is not fully clarified
and whether CGRP antagonism may represent a useful
therapeutic approach for the treatment of chronic pain
is unknown.
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The aim of this systematic review was to assess the
role of CGRP in non-headache pain in humans. In
addition we discussed the potential role of anti-CGRP
agents in the management of chronic pain.
Methods
Literature search
We performed a systematic literature search identifying
articles reporting original data on CGRP and non-
headache pain. We concluded the literature search on
Pubmed Embase and ClinicalTrials.gov on May 2016.
We used the following search terms: CGRP and pain. In
addition, we specified our search criteria in Clinical-
Trials.gov to currently available monoclonal antibodies
against CGRP (LY2951742, ALD-403, PF-04427429,
LBR-101/TEV-48125) or its receptor (AMG334), and
CGRP receptor antagonists (BIBN4096BS, MK-0974,
MK-3207, MK-1602, MK-8825, BMS-694153, BMS-
927711, BMS-742413, BI 44370 TA) [16].
Only human studies published in English language
were included. Review papers editorials and other
articles without original data were excluded. We also
considered articles from the reference list of studies that
were found to be relevant as well as literature that was
known to be relevant by the authors.
Data extraction
The authors (WSS) examined the abstracts found in the
literature search. Whenever the title or abstract sug-
gested that relevant data could be part of the publication
the entire article was read and discussed with the other
co-authors. Studies in which patients had unclear pain
history or articles without relevant data on CGRP were
not included in the review.
Results
Our Pubmed Embase and ClinicalTrials search strategy
identified 375 hits of which 50 studies were included in
the final review (Fig. 1). After excluding 110 as duplicates,
another 118 hits were excluded because these were ab-
stracts, reviews, animal, migraine, headache studies, and
incomplete studies. Subsequently, we excluded 97 studies
that did not describe pain history of the patients, had no
relevant data on CGRP, or had unclear methodology. In
total, 50 studies were included in the final review (Fig. 1).
The identified studies were further divided into five cat-
egories: 1) somatic pain, 2) visceral pain, 3) inflammatory
pain, 4) neuropathic pain, and 5) clinical trials (Fig. 2).
Somatic pain
We found a total of 20 studies on the role of CGRP in
somatic pain (Table 1). Using different methodological
approaches and CGRP sample sources 13 studies
showed higher levels of CGRP compared to controls.
Eight studies directly tested for a possible correlation be-
tween pain intensity and CGRP levels. In chronic knee
pain due to osteoarthrosis elevated CGRP levels were
detected in serum and synovial fluid in patients com-
pared with controls. Serum CGRP levels were positively
correlated with pain intensity [17]. Chronic low back pa-
tients due to osteoarthrosis showed decreased blood
CGRP levels four months after successful auricular point
acupressure pain treatment compared to baseline. No
decrease was found in patients who received sham treat-
ment [18]. In addition, studies using immunofluorescence
Fig. 1 Flow chart of the study
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of skin biopsies reported decreased CGRP after acupunc-
ture treatment of osteoarthrosis patients [19]. Immunohis-
tochemistry analysis of synovial tissue from fossa acetabuli
showed increased CGRP levels in patients compared to
controls [20, 21]. One study reported higher levels of CGRP
in hip synovium from osteoarthritis patients compared with
femoral neck patients [22]. Moreover, one study [23] re-
vealed higher levels of CGRP in synovial tissue from tem-
poromandibular joint (TMJ) pain patients compared with
controls. This study also reported positive correlation
between pain and CGRP levels [23]. Biopsies from
knee joint ligaments showed no difference in CGRP
nerve density between patients and non-arthrosis
patients [24]. In patients with osteoarthrosis CGRP
concentration in cerebrospinal fluid was decreased
compared to controls [25].
In patients suffering from chronic pain due to degen-
erative disc disease disc biopsies showed increased
CGRP compared to post-mortem control discs [26].
Biopsies from intervertebral discs in patients with low
back pain contained CGRP-IR nerve fibers [27].
Patients suffering from shoulder and neck pain due to
whiplash injury were found to have higher blood CGRP
levels compared to controls [28]. Another study of pa-
tients with disc herniation pain reported increased blood
levels of CGRP which were normalized after discectomy
[29]. Blood CGRP levels were also elevated in patients
with soft tissue injury (i.e. muscle or ligament pain)
Fig. 2 Overview of the studies in non-headache pain included in each category in the present review
Schou et al. The Journal of Headache and Pain  (2017) 18:34 Page 3 of 17
Ta
b
le
1
St
ud
ie
s
on
th
e
ro
le
of
C
G
RP
in
so
m
at
ic
pa
in
St
ud
y
O
bj
ec
tiv
es
Re
po
rt
ed
pa
in
as
pa
rt
of
ph
en
ot
yp
e
M
et
ho
d
an
d
sa
m
pl
e
si
ze
So
ur
ce
of
C
G
RP
Re
su
lts
D
ur
at
io
n
of
th
e
in
ve
st
ig
at
ed
co
nd
iti
on
C
or
re
la
tio
n
be
tw
ee
n
C
G
RP
le
ve
la
nd
pa
in
A
lp
ar
,2
00
2
[1
]
D
et
er
m
in
e
pl
as
m
a
C
G
RP
in
pa
tie
nt
s
w
ith
w
hi
pl
as
h
in
ju
ry
w
ho
w
er
e
tr
ea
te
d
by
ca
rp
al
tu
nn
el
de
co
m
pr
es
si
on
C
hr
on
ic
sh
ou
ld
er
an
d
ne
ck
pa
in
du
e
to
w
hi
pl
as
h
in
ju
ry
38
pa
tie
nt
s
an
d
11
co
nt
ro
ls
.
En
zy
m
e-
im
m
un
oa
ss
ay
ki
t
w
as
us
ed
to
m
ea
su
re
th
e
pl
as
m
a
C
G
RP
Bl
oo
d
(p
la
sm
a)
M
ea
n
pl
as
m
a
le
ve
ls
w
as
hi
gh
er
in
pa
tie
nt
s,
40
0
ng
/l,
th
an
in
co
nt
ro
ls
,8
5
ng
/l.
Pl
as
m
a
le
ve
ls
w
er
e
re
du
ce
d,
65
ng
/l,
af
te
r
ca
rp
al
tu
nn
el
de
co
m
pr
es
si
on
N
R
Re
du
ce
d
pl
as
m
a
C
G
RP
af
te
r
th
e
op
er
at
io
n
co
rr
el
at
ed
to
th
e
pa
in
re
du
ct
io
n
Bj
ur
,2
00
5
[2
]
In
ve
st
ig
at
e
in
ne
rv
at
io
n
pa
tt
er
ns
of
A
ch
ill
es
te
nd
on
in
te
nd
in
os
is
te
nd
on
,
an
d
no
rm
al
te
nd
on
C
hr
on
ic
pa
in
in
te
nd
in
os
is
Ti
ss
ue
sa
m
pl
es
fro
m
21
pa
tie
nt
s
an
d
9
co
nt
ro
ls
Ti
ss
ue
bi
op
si
es
(A
ch
ill
es
te
nd
on
)
In
co
nc
lu
si
ve
.C
G
RP
w
as
fo
un
d
in
bo
th
pa
tie
nt
s
an
d
co
nt
ro
ls
.T
he
am
ou
nt
of
C
G
RP
-fi
be
rs
w
as
no
t
qu
an
tif
ie
d
M
ea
n
19
m
on
th
s
N
R
Br
ow
n,
19
97
[3
]
D
et
er
m
in
e
de
ns
ity
of
C
G
RP
co
nt
ai
ni
ng
se
ns
or
y
ne
rv
e
fib
er
s
in
ve
rt
eb
ra
le
nd
pl
at
e
in
pa
tie
nt
s
w
ith
de
ge
ne
ra
tiv
e
di
sc
di
se
as
e
Se
ve
re
ba
ck
pa
in
w
ith
or
w
ith
ou
t
sc
ia
tic
a
in
de
ge
ne
ra
tiv
e
di
sc
di
se
as
e
Ti
ss
ue
fro
m
th
e
in
te
rv
er
te
br
al
di
sc
s
fro
m
15
pa
tie
nt
s
un
de
rg
oi
ng
an
te
rio
r
lu
m
ba
r
di
sc
ec
to
m
y
an
d
7
he
al
th
y
po
st
-
m
or
te
m
co
nt
ro
ls
Ti
ss
ue
bi
op
si
es
(in
te
rv
er
te
br
al
di
sc
s)
M
ar
ke
d
in
cr
ea
se
in
C
G
RP
-
co
nt
ai
ni
ng
se
ns
or
y
ne
rv
e
fi-
be
rs
co
m
pa
re
d
w
ith
co
nt
ro
ls
N
R
N
R
C
ar
ls
so
n,
20
06
[4
]
Ev
al
ua
te
po
ss
ib
le
ef
fe
ct
s
of
ac
up
un
ct
ur
e
on
se
ns
or
y
ne
rv
e
fib
er
s
in
hu
m
an
sk
in
C
er
vi
co
br
ac
hi
al
pa
in
,
ce
rv
ic
oc
ra
ni
al
pa
in
,h
ip
pa
in
an
d
fin
ge
r
pa
in
fro
m
ar
th
ro
si
s
Pu
nc
h
sk
in
bi
op
si
es
ta
ke
n
fro
m
6
pa
tie
nt
s
on
e
w
ee
k
be
fo
re
ac
up
un
ct
ur
e
an
d
3–
6
da
ys
af
te
r
th
e
10
th
tr
ea
tm
en
t
Ti
ss
ue
bi
op
si
es
(s
ki
n)
Th
e
m
ea
n
nu
m
be
r
of
C
G
RP
-
IR
ne
rv
e
fib
er
s
w
er
e
re
du
ce
d
af
te
r
tr
ea
tm
en
t
4
m
on
th
s
-
>
10
ye
ar
s
N
R
D
an
ie
ls
on
,
20
08
[5
]
In
ve
st
ig
at
e
C
G
RP
pr
ev
al
en
ce
in
pa
tie
nt
s
w
ith
te
nd
in
iti
s
su
rg
er
y.
C
hr
on
ic
pa
in
fu
l
pa
te
lla
r
te
nd
in
os
is
Pa
te
lla
r
te
nd
on
bi
op
sy
in
7
pa
tie
nt
s
Ti
ss
ue
bi
op
si
es
(p
at
el
la
r
te
nd
on
)
C
G
RP
ra
re
ly
de
te
ct
ed
at
pe
riv
as
cu
la
r
si
te
s
C
hr
on
ic
pa
in
N
R
D
on
g,
20
15
[6
]
Ex
am
in
e
C
G
RP
co
nc
en
tr
at
io
ns
in
pa
tie
nt
s
w
ith
pr
im
ar
y
kn
ee
O
A
an
d
co
nt
ro
ls
C
hr
on
ic
kn
ee
pa
in
fro
m
O
A
Se
ru
m
C
G
RP
co
nc
en
tr
at
io
ns
in
O
A
pa
tie
nt
s
(n
=
65
)
an
d
co
nt
ro
ls
(n
=
21
).
Bl
oo
d
(s
er
um
)
C
G
RP
le
ve
ls
w
er
e
hi
gh
er
in
pa
tie
nt
s,
2.
43
ng
/m
L,
th
an
in
co
nt
ro
ls
,1
.9
5
ng
/m
L
N
R
C
G
RP
co
nc
en
tr
at
io
ns
in
se
ru
m
w
er
e
co
rr
el
at
ed
w
ith
pa
in
in
te
ns
ity
Ik
eu
ch
i,
20
12
[7
]
D
et
er
m
in
e
se
ns
or
y
in
ne
rv
at
io
n
of
po
st
er
io
r
cr
uc
ia
te
lig
am
en
t
(P
C
L)
in
pa
tie
nt
s
w
ith
O
A
C
hr
on
ic
kn
ee
pa
in
fro
m
O
A
PC
L
sa
m
pl
es
fro
m
10
pa
tie
nt
s
an
d
5
pa
in
-fr
ee
co
nt
ro
ls
w
ith
an
te
rio
r
cr
uc
ia
te
lig
am
en
t
(A
C
L)
ru
pt
ur
e
Ti
ss
ue
bi
op
si
es
(jo
in
t
lig
am
en
t)
N
o
di
ffe
re
nc
e
be
tw
ee
n
pa
tie
nt
s
an
d
co
nt
ro
ls
N
R
N
R
Jo
nh
ag
en
,
20
06
[8
]
D
et
er
m
in
e
C
G
RP
in
hu
m
an
sk
el
et
al
m
us
cl
e
at
re
st
an
d
af
te
r
pa
in
fu
l
ec
ce
nt
ric
ex
er
ci
se
Ex
pe
rim
en
ta
l
m
us
cl
e
pa
in
af
te
r
ec
ce
nt
ric
ex
er
ci
se
M
ic
ro
di
al
ys
is
ca
th
et
er
in
se
rt
ed
in
qu
ad
ric
ep
s
m
us
cl
e
in
8
he
al
th
y
vo
lu
nt
ee
rs
.S
am
pl
es
ta
ke
n
be
fo
re
an
d
af
te
r
ex
er
ci
se
.
Bl
oo
d
(p
la
sm
a)
C
G
RP
le
ve
ls
w
er
e
hi
gh
er
2
da
ys
af
te
r
ex
er
ci
se
,5
.4
fm
ol
/m
l,
th
an
di
re
ct
ly
af
te
r
ex
er
ci
se
,4
.8
5
fm
ol
/m
l
VA
S-
sc
or
e
w
as
as
se
ss
ed
on
th
e
en
tr
y
da
y
(V
A
S
=
0)
,
da
y
1
(V
A
S
=
1)
an
d
da
y
3
(V
A
S
=
2)
af
te
r
th
e
ex
er
ci
se
C
G
RP
co
nc
en
tr
at
io
ns
w
as
po
si
tiv
el
y
co
rr
el
at
ed
w
ith
pa
in
in
te
ns
ity
(V
A
S)
La
rs
so
n,
19
91
[9
]
In
ve
st
ig
at
e
C
G
RP
-le
ve
ls
fro
m
pa
tie
nt
s
w
ith
rh
eu
m
at
oi
d
ar
th
rit
is
an
d
pa
tie
nt
s
w
ith
m
en
is
ca
l/c
ru
ci
at
e
lig
am
en
t
in
ju
rie
s
A
cu
te
kn
ee
pa
in
in
m
en
is
ca
l/
cr
uc
ia
te
lig
am
en
t
in
ju
rie
s
Sy
no
vi
al
flu
id
fro
m
th
e
kn
ee
jo
in
t
of
18
pa
tie
nt
s
an
d
13
pa
in
-fr
ee
co
nt
ro
ls
w
ith
lig
am
en
t
in
ju
rie
s
Sy
no
vi
al
flu
id
(k
ne
e
jo
in
t)
In
cr
ea
se
d
C
G
RP
le
ve
ls
in
pa
tie
nt
s
co
m
pa
re
d
to
co
nt
ro
ls
.
4-
27
ye
ar
s
N
R
Schou et al. The Journal of Headache and Pain  (2017) 18:34 Page 4 of 17
Ta
b
le
1
St
ud
ie
s
on
th
e
ro
le
of
C
G
RP
in
so
m
at
ic
pa
in
(C
on
tin
ue
d)
Li
n,
20
15
[1
0]
In
ve
st
ig
at
e
as
so
ci
at
io
ns
be
tw
ee
n
pl
as
m
a
C
G
RP
-le
ve
ls
an
d
cl
in
ic
al
ou
t-
co
m
e
fro
m
A
PA
,i
n
pa
tie
nt
s
w
ith
os
te
oa
rt
hr
iti
s
an
d
sp
in
al
st
en
os
is
C
hr
on
ic
lo
w
er
ba
ck
pa
in
(C
LB
P)
in
pa
tie
nt
s
w
ith
os
te
oa
rt
hr
iti
s
an
d
sp
in
al
st
en
os
is
Bl
oo
d
sa
m
pl
es
fro
m
32
pa
tie
nt
s
(A
PA
-g
ro
up
)
an
d
29
co
nt
ro
ls
(s
ha
m
A
PA
-g
ro
up
).
Sa
m
pl
es
w
er
e
ta
ke
n
at
ba
se
lin
e
an
d
4
w
ee
ks
la
te
r.
VA
S-
sc
or
e
be
fo
re
tr
ea
tm
en
t
w
as
4.
Bl
oo
d
(p
la
sm
a)
Pa
tie
nt
s
sh
ow
ed
a
de
cr
ea
se
in
C
G
RP
le
ve
ls
af
te
r
tr
ea
tm
en
t.
N
o
de
cr
ea
se
in
th
e
co
nt
ro
lg
ro
up
A
t
le
as
t
3
m
on
th
s
56
%
of
th
e
pa
tie
nt
gr
ou
p
re
po
rt
ed
a
re
du
ct
io
n
in
pa
in
,
w
he
re
as
on
ly
9%
co
nt
ro
ls
re
po
rt
ed
a
re
du
ct
io
n
Li
nd
h,
19
99
[1
1]
D
et
er
m
in
e
C
G
RP
-L
Il
ev
el
s
in
C
SF
in
pa
tie
nt
s
w
ith
ch
ro
ni
c
pa
in
O
st
eo
ar
th
rit
is
,
he
rn
ia
te
d
lu
m
ba
r
di
sc
an
d
hi
p
fra
ct
ur
e
pa
in
Sa
m
pl
e:
C
SF
Su
bj
ec
ts
:3
5
pa
tie
nt
s
(1
4
ha
d
kn
ee
or
hi
p
pa
in
,1
1
ha
d
rh
iz
op
at
hi
c
pa
in
du
e
to
he
rn
ia
te
d
lu
m
ba
r
pa
in
,1
0
ha
d
pa
in
fro
m
hi
p
fra
ct
ur
e
an
d
12
he
al
th
y
co
nt
ro
ls
.
Pa
in
as
se
ss
m
en
t:
VA
S
C
SF
D
ec
re
as
ed
C
G
RP
-L
Il
ev
el
s
w
er
e
ob
se
rv
ed
in
pa
tie
nt
s
co
m
pa
re
d
to
he
al
th
y
co
nt
ro
ls
O
st
eo
ar
th
rit
is
pa
tie
nt
s:
>
6
m
on
th
s.
Rh
iz
op
at
hi
c
pa
in
:A
t
le
as
t
1
m
on
th
(1
–
13
).
H
ip
fra
ct
ur
e
pa
in
:U
p
to
48
h
N
o
co
rr
el
at
io
n
be
tw
ee
n
C
G
RP
-L
Il
ev
el
s
an
d
VA
S-
va
lu
es
co
ul
d
be
ob
se
rv
ed
fo
r
an
y
of
th
e
su
bj
ec
ts
pa
rt
ic
ip
at
-
in
g
in
th
e
st
ud
y
O
nu
oh
a,
19
99
[1
2]
In
ve
st
ig
at
e
C
G
RP
le
ve
ls
in
pa
tie
nt
s
w
ith
so
ft
tis
su
e
in
ju
ry
A
cu
te
m
us
cl
e
an
d
lig
am
en
t
pa
in
du
e
to
in
ju
ry
Pl
as
m
a
C
G
RP
-c
on
ce
nt
ra
tio
ns
in
17
pa
tie
nt
s
an
d
15
he
al
th
y
co
nt
ro
ls
Bl
oo
d
(P
la
sm
a)
C
G
RP
-le
ve
ls
w
er
e
si
gn
ifi
ca
nt
ly
hi
gh
er
in
pa
tie
nt
s
th
an
co
nt
ro
ls
U
p
to
24
h
N
R
O
za
w
a,
20
06
[1
3]
To
de
te
rm
in
e
se
ns
or
y
fib
er
s
in
ne
rv
at
in
g
hu
m
an
de
ge
ne
ra
te
d
lu
m
ba
r
in
te
rv
er
te
br
al
di
sc
s
D
is
co
ge
ni
c
lo
w
ba
ck
pa
in
Lu
m
ba
r
in
te
rv
er
te
br
al
di
sc
w
as
ha
rv
es
te
d
fro
m
8
pa
tie
nt
s,
an
d
im
m
un
os
ta
in
ed
fo
r
C
G
RP
Ti
ss
ue
bi
op
si
es
(in
te
rv
er
te
br
al
di
sc
)
C
G
RP
-IR
ne
rv
e
fib
er
s
w
er
e
ob
se
rv
ed
in
6
ou
t
of
8
pa
tie
nt
s
N
R
N
R
Sa
m
ue
ls
so
n,
19
93
[1
4]
D
et
er
m
in
e
C
SF
C
G
RP
le
ve
ls
in
ca
nc
er
pa
tie
nt
s
C
an
ce
r
pa
in
C
SF
fro
m
10
pa
tie
nt
s
co
m
pa
re
d
w
ith
10
co
nt
ro
ls
C
SF
N
o
di
ffe
re
nc
e
in
C
G
RP
-le
ve
ls
be
tw
ee
n
pa
tie
nt
s
an
d
co
nt
ro
ls
N
R
N
o
di
ffe
re
nc
e
be
tw
ee
n
pa
tie
nt
s
w
ith
pa
in
an
d
co
nt
ro
ls
Sa
sa
ki
,2
01
3
[1
5]
In
ve
st
ig
at
e
in
ne
rv
at
io
n
pa
tt
er
ns
of
EC
RB
in
pa
tie
nt
s
w
ith
re
ca
lc
itr
an
t
te
nn
is
el
bo
w
La
te
ra
l
ep
ic
on
dy
lit
is
Ti
ss
ue
bi
op
si
es
fro
m
8
pa
tie
nt
s
an
d
2
co
nt
ro
ls
.T
he
co
nt
ro
l
gr
ou
p
su
ffe
re
d
fro
m
os
te
oc
ho
nd
rit
is
Ti
ss
ue
bi
op
si
es
(la
te
ra
l
ep
ic
on
dy
le
)
A
de
cr
ea
se
in
th
e
im
m
un
or
ec
tiv
ity
of
C
G
RP
co
m
pa
re
d
to
co
nt
ro
ls
M
ea
n
du
ra
tio
n
23
m
on
th
s
Th
e
in
ne
rv
at
io
n
pa
tt
er
n
di
d
no
t
ap
pe
ar
to
be
co
rr
el
at
ed
w
ith
VA
S-
sc
or
e
Sa
to
,2
00
4
[1
6]
El
uc
id
at
e
ex
pr
es
si
on
of
C
G
RP
in
te
m
po
ro
m
an
di
bu
la
r
jo
in
t
(T
M
J)
fro
m
pa
tie
nt
s
w
ith
in
te
rn
al
de
ra
ng
em
en
t
TM
J
pa
in
Sy
no
vi
al
flu
id
fro
m
48
pa
tie
nt
s
an
d
7
co
nt
ro
ls
,w
ho
ha
d
pa
in
-
fre
e
ha
bi
tu
al
di
sl
oc
at
io
n
Sy
no
vi
al
flu
id
(T
M
J)
In
cr
ea
se
d
C
G
RP
in
pa
tie
nt
s
co
m
pa
re
d
to
co
nt
ro
ls
M
ea
n
du
ra
tio
n
6
m
on
th
s
Po
si
tiv
e
co
rr
el
at
io
n
be
tw
ee
n
th
e
ex
te
nt
sc
or
e
of
C
G
RP
-le
ve
ls
an
d
jo
in
t
pa
in
Sa
xl
er
,2
00
7
[1
7]
D
et
er
m
in
e
pr
es
en
ce
of
C
G
RP
-
im
m
un
op
os
iti
ve
ne
rv
e
fib
er
s
in
pa
-
tie
nt
s
w
ith
O
A
H
ip
pa
in
fro
m
O
A
So
ft
tis
su
e
bi
op
si
es
fro
m
fo
ss
a
ac
et
ab
ul
ii
n
3
pa
tie
nt
s
an
d
6
pa
in
-fr
ee
co
nt
ro
ls
.3
co
nt
ro
ls
ha
d
a
fa
ile
d
TH
A
an
d
3
co
nt
ro
ls
ha
d
fe
m
or
al
ne
ck
fra
ct
ur
es
Ti
ss
ue
bi
op
si
es
(fo
ss
a
ac
et
ab
ul
i)
In
cr
ea
se
d
C
G
RP
-L
Ii
n
pa
-
tie
nt
s
co
m
pa
re
d
to
co
nt
ro
ls
.
N
R
Po
si
tiv
e
co
rr
el
at
io
n
be
tw
ee
n
C
G
RP
an
d
pa
in
Ta
ke
sh
ita
,
20
12
[1
8]
C
la
rif
y
se
ns
or
y
in
ne
rv
at
io
n
an
d
in
fla
m
m
at
or
y
cy
to
ki
ne
s
in
O
A
pa
tie
nt
s
Se
ve
re
hi
p
pa
in
fro
m
O
A
Sy
no
vi
um
fro
m
50
pa
tie
nt
s
an
d
12
co
nt
ro
ls
w
ith
fe
m
or
al
ne
ck
fra
ct
ur
e
Sy
no
vi
al
flu
id
(h
ip
)
C
G
RP
-IR
se
ns
or
y
ne
rv
e
fib
er
s
w
er
e
ob
se
rv
ed
in
54
%
of
th
e
pa
tie
nt
s
an
d
0%
in
co
nt
ro
ls
N
R
N
R
Ta
ke
uc
hi
,
20
07
[1
9]
D
et
er
m
in
e
C
G
RP
’s
ro
le
in
pa
tie
nt
s
w
ith
lu
m
ba
r
di
sc
he
rn
ia
tio
n,
be
fo
re
an
d
af
te
r
lu
m
ba
r
di
sc
ec
to
m
y
Sc
ia
tic
pa
in
/
lu
m
ba
r
di
sc
he
rn
ia
tio
n
Pl
as
m
a
C
G
RP
w
as
m
ea
su
re
d
in
27
pa
tie
nt
be
fo
re
an
d
3
w
ee
ks
af
te
r
lu
m
ba
r
di
sc
ec
to
m
y
Bl
oo
d
(p
la
sm
a)
Pl
as
m
a
C
G
RP
-le
ve
ls
w
er
e
re
-
du
ce
d
af
te
r
lu
m
ba
r
di
sc
ec
to
m
y
3
w
ee
ks
Re
du
ce
d
pl
as
m
a
C
G
RP
af
te
r
th
e
op
er
at
io
n
co
rr
el
at
ed
to
lo
w
er
VA
S-
le
ve
ls
Schou et al. The Journal of Headache and Pain  (2017) 18:34 Page 5 of 17
Ta
b
le
1
St
ud
ie
s
on
th
e
ro
le
of
C
G
RP
in
so
m
at
ic
pa
in
(C
on
tin
ue
d)
W
an
g,
20
15
[2
0]
Ex
pl
or
e
m
ec
ha
ni
sm
s
of
po
ss
ib
le
in
vo
lv
em
en
t
an
d
re
gu
la
tio
n
of
C
G
RP
in
pa
th
ol
og
ic
al
an
d
in
fla
m
m
at
or
y
pr
oc
es
se
s
of
ar
th
rit
is
in
pa
tie
nt
s
w
ith
de
ve
lo
pm
en
ta
ld
ys
pl
as
ia
of
th
e
hi
p
(D
D
H
)
H
ip
pa
in
fro
m
O
A
Sy
no
vi
al
tis
su
e
sa
m
pl
es
fro
m
67
pa
tie
nt
s:
35
w
ith
m
od
er
at
e
D
D
H
an
d
32
pa
tie
nt
s
w
ith
se
ve
re
D
D
H
.
15
co
nt
ro
ls
w
ith
tr
au
m
at
ic
fe
m
or
al
fra
ct
ur
e
Sy
no
vi
al
tis
su
e
(fo
ss
a
ac
et
ab
ul
i)
In
cr
ea
se
d
C
G
RP
in
sy
no
vi
um
flu
id
fro
m
pa
tie
nt
s
in
th
e
se
ve
re
D
D
H
gr
ou
p
co
m
pa
re
d
to
th
e
m
od
er
at
e
D
D
H
gr
ou
p
an
d
co
nt
ro
ls
N
R
Th
e
hi
gh
es
t
am
ou
nt
of
C
G
RP
co
rr
el
at
ed
w
ith
th
e
hi
gh
es
t
VA
S
A
PA
A
ur
ic
ul
ar
po
in
t
ac
up
re
ss
ur
e,
CG
RP
C
al
ci
to
ni
n
ge
ne
-r
el
at
ed
pe
pt
id
e,
CG
RP
-L
IC
al
ci
to
ni
n
ge
ne
-r
el
at
ed
pe
pt
id
e-
lik
e
im
m
un
or
ea
ct
iv
ity
,C
LB
P
C
hr
on
ic
lo
w
ba
ck
pa
in
,C
RP
S
C
om
pl
ex
re
gi
on
al
pa
in
sy
nd
ro
m
e,
CS
F
C
er
eb
ro
sp
in
al
flu
id
,E
CR
B
Ex
te
ns
or
ca
rp
ir
ad
ia
lis
br
ev
is
,K
L
gr
ad
es
Ke
llg
re
en
an
d
La
w
re
nc
e
cl
as
si
fic
at
io
n,
us
ed
to
as
se
ss
th
e
se
ve
rit
y
of
O
A
,N
R
no
t
re
po
rt
ed
,O
A
O
st
eo
ar
th
rit
is
,P
H
N
Po
st
he
rp
et
ic
ne
ur
al
gi
a,
TH
A
To
ta
l
hi
p
ar
th
ro
pl
as
tie
s
Schou et al. The Journal of Headache and Pain  (2017) 18:34 Page 6 of 17
compared with controls [30]. Furthermore, one radio-
immunoassay study of knee synovial fluid from patients
with meniscal or ligament injury revealed higher CGRP
levels compared to controls [31].
Immunohistochemistry analysis of biopsies of Achilles
tendons from patients with chronic painful tendinosis
showed no changes in CGRP levels in patients compared
to controls [32] while another study in patients with
patellar tendinosis found the presence of CGRP, but had
no control group [33]. One study reported decreased
CGRP in the extensor carpi radialis brevis tendon biopsy
from patients with tennis elbow compared to patients
with osteochondritis [34].
Samuelsson and colleagues [35] compared CGRP levels
in cerebrospinal fluid from cancer patients with pain and
found no difference between patients and non-pain con-
trol patients. A microdialysis study in the vastus lateralis
of the quadriceps muscles before and during pain after
eccentric exercise (repetitive muscle contractions while
the muscle is lengthening under load) reported increased
CGRP levels during pain compared with baseline [36].
Visceral pain
Eight studies examined CGRP in different types of vis-
ceral pain conditions (Table 2).
Immunofluorescence-based analysis of peritoneal fluid
obtained during diagnostic laparoscopy in patients with
endometriosis showed increased CGRP levels compared
to peritoneal fluid from controls without endometriosis
[37]. Visual analogue scale scores were registered in all
patients but authors found no correlation between
CGRP levels and severity of pain. Immunohistochemistry
analyses of peritoneal endometriotic lesions and normal
peritoneum from non-endometriotic women showed in-
creased CGRP in affected tissue material [38]. Using the
same technique, increased CGRP levels were found in
endometrium and myometrium in women with, but not
in those without endometriosis. Pain measurement data
was not reported [39]. CGRP levels were also studied in
patients with vulvodynia. Analysis of vulval vestibule
tissue revealed no differences in CGRP levels between
patients with vulvodynia and controls [40].
Gastric mucosal biopsies from patients with non-
erosive reflux disease [41] and functional dyspepsia [42]
were investigated with enzyme- and radioimmunoassay.
None of the studies found differences in CGRP levels be-
tween patients and controls but a negative correlation
between CGRP concentrations and pain scores was re-
ported in the latter [42]. CGRP has also been investi-
gated with immunohistochemistry in patients with
alcohol-based painful chronic pancreatitis and increased
CGRP levels in patients were reported compared with
pancreatic tissue from organ donors [43].
Plasma CGRP levels were studied in patients with sus-
pected or definite acute myocardial infarction at admis-
sion at a coronary care unit [44]. This study revealed no
difference in CGRP levels between patients with and
without acute myocardial infarction and no difference
between patients with pain and those without pain.
Inflammatory pain
Eight studies on CGRP and inflammatory pain condi-
tions were identified (Table 3). ELISA of dermal micro-
dialysate from volar forearm showed elevated blood
CGRP levels in ten healthy volunteers with capsaicin-
induced pain [45]. No CGRP release was detected via
dermal microdialysate after electrical stimulation in the
same area. Correlation between pain intensity or thresh-
old and CGRP concentration was not tested [45]. In
contrast another study found CGRP in the dialysate after
histamine iontophoresis, but not after capsaicin applica-
tion in the volar forearm [46]. One study performed im-
munohistochemistry of skin biopsies after intradermal
capsaicin injection and reported complete loss of CGRP
visualization 72 h after injection [47].
Using the ELISA and dermal microdialysis method in
healthy volunteers CGRP release was reported after
electrical stimulation upon phosphoramidon but not
after captopril infusion in the volar forearm [48]. Phos-
phoramidon and captopril, respectively, inhibit neutral
endopeptidase and angiotensin-converting hormone,
which are both involved in neuropeptide degradation [49].
Immunohistochemical analysis of skin biopsies in pa-
tients with painful scars from burn showed increased
CGRP compared with controls with burn scars without
pain [50]. Another study reported increased CGRP in
hypertrophic burn scar compared to biopsies from un-
burned scars. Pain intensity was higher in patients with
burn scars [51]. Moreover ELISA of peripheral blood
showed increased CGRP levels up to 24 h after burn
injuries compared with healthy volunteers [52] and in pa-
tients with pruritus due to atopic dermatitis [53]. Further-
more, CGRP levels were positively correlated with the
severity of pruritus [53]. Nociceptive fibers have been
shown to be involved in the sensation of pruritus [54].
Neuropathic pain
We identified 11 studies in this category (Table 4).
Radioimmunoassay showed higher serum CGRP levels
in 19 patients with complex regional pain syndrome
(CRPS) compared to controls. The difference was nor-
malized after a 9-month pain management therapy [55].
In contrast another study found decreased serum CGRP
levels in chronic CRPS patients (n = 12) compared with
healthy controls [56]. No correlation between pain and
CGRP levels was found in either study [55, 56]. More-
over, immunofluorescence analysis of skin biopsies from
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amputated limbs in CRPS patients showed loss of CGRP
expression in two patients compared with skin biopsies
from five controls. Correlation between pain measures
and CGRP levels was not tested [57]. In post-herpetic
neuralgia, increased CGRP expression in the affected
skin compared with skin from a contralateral side in the
same patient was reported by using immunofluorescence
analyses of skin biopsies [58]. In one study using im-
munofluorescence of skin biopsies [59] no difference in
CGRP expression was found between patients with
chronic pain due to nerve injury after hand surgery and
controls. The immunohistochemistry of peripheral nerve
biopsies harvested from patients with Morton’s neur-
oma, which results in neuropathic pain, showed in-
creased amount of CGRP in patients compared with
controls [60].
Four studies reported on CGRP radioimmunoassay: 1)
gingival crevicular fluid in unilateral tooth pain patients
[61] 2) saliva from burning mouth syndrome patients
[62, 63], and 3) pulp biopsy in patients undergoing
orthodontic intrusion [64]. None of the studies reported
alteration in CGRP expressions in painful sides when
compared with the non-painful side [61] or with
controls [62, 64].
Attal et al. [65] investigated 152 patients with periph-
eral neuropathic pain of whom 68 were treated with
botulinum toxin A and 66 received placebo. CGRP was
analyzed in skin biopsies using ELISA at week 1 and 4 in
23 patients who received botulinum toxin A and in 17
patients who received placebo. No difference between
groups was found [65].
CGRP antagonists and antibodies and clinical trials
We did not identify any clinical trials on CGRP antagonists
and antibodies for the treatment of non-headache pain by
searching PubMed and Embase. Search on ClinicalTrial.gov
for current CGRP antagonists and antibodies for the treat-
ment of non-headache pain only yielded three studies.
The acute effect of PF-04427429 anti-CGRP monoclo-
nal antibody, on attenuation of flare response after cap-
saicin challenge, used to induce experimental human
pain, was studied in a double blind, randomized,
placebo-controlled, third-party open, modified cross-
over study in male healthy volunteers and using EMLA®
cream as positive control [66]. However, primary out-
come measure of the study was mean blood perfusion
induced by capsaicin challenge (results not reported on
ClinicalTrials.gov) and no pain perception measures
were studied.
A phase 2 randomized, double-blind, placebo and
active-controlled trial in patients with mild to moderate
osteoarthritis knee pain failed to demonstrate efficacy of
LY2951742, monoclonal antibody to CGRP [67]. The
study was terminated. A total of 266 patients were
randomized to 1 of 6 treatment arms: LY2951742 5 mg,
50 mg, 120 mg, or 300 mg, celecoxib 200 mg, or pla-
cebo. Using a Bayesian dose–response longitudinal
model, response rates to all four LY2951742 treatment
arms were not different from placebo while celecoxib
met criteria for a positive study [68].
An ongoing study on remote ischemic conditioning in
patients with ulcerative colitis a condition associated
with abdominal pain and diarrhea is still in a recruiting
phase [69]. Investigators plan to study changes of serum
and mucosal CGRP levels (secondary endpoints) in pa-
tients with ischemic colitis after remote ischemic condi-
tioning, a repeated brief and non-harmful suppression of
blood circulation induced by placing a blood pressure
cuff around the right or left arm.
Discussion
Summary of findings
The present review revealed the association between
measured CGRP levels and somatic visceral, neuropathic
and inflammatory pain. We found that in somatic pain
conditions in particular, CGRP levels correlated with
pain. Increased CGRP levels were reported in plasma,
synovial and cerebrospinal fluid, tissue biopsies in indi-
viduals with degenerative disc disease, osteoarthritis and
TMJ-pain. Furthermore, CGRP was elevated in acute
pain conditions and pain after exercise.
In total 13 out of 20 studies on somatic pain increased
levels of CGRP were reported. Five studies showed no
difference or had no control group. Four out of eight
studies investigated CGRP in experimental models of in-
flammatory pain. The remaining four studies reported
elevated CGRP levels in patients with pain caused by
scars and pruritus. There was no consensus regarding
correlation between neuropathic pain and CGRP levels.
Six out of eleven studies showed no difference in CGRP
levels, three studies reported a positive correlation, and
two studies reported a negative correlation between
neuropathic pain and CGRP levels. In visceral pain
conditions a correlation between gynecological pain and
high CGRP levels were found in tissue biopsies and peri-
toneal fluid. However, only two studies used a control
group or control conditions.
Thirty out of fifty studies (60%) included controls and
suggested an association between CGRP levels and the
respective pain condition. Twenty-six (52%) studies re-
ported a positive association whereas four studies (8%)
reported decreased CGRP levels. Studies reporting posi-
tive association investigated blood (10 studies), skin (5
studies), synovial tissue/fluid (5 studies), and other af-
fected tissues (6 studies). Collectively, these studies
showed a positive correlation between high CGRP levels
and somatic pain conditions, especially osteoarthritis,
acute muscular pain and chronic joint/muscular pain.
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These findings raise two important questions: what is
the role of CGRP in the transmission of nociceptive
signals and whether CGRP causes or modulates pain?
CGRP and pathophysiology of pain
CGRP is widely distributed in the peripheral and central
nervous system [70, 71] and CGRP receptors are
expressed in pain pathways [72–76]. CGRP-like immu-
noreactivity (CGRP-LI) is found in 40–50% of dorsal
root ganglia (DRG) neurons [77]. CGRP-LI was found
C-fiber (46%), delta-fiber (33%), and A-alpha/beta fiber
(17%) neurons [77]. Moreover, CGRP is usually co-
localized with other neuropeptides, including substance
P [78] and neurokinins [79] in DRG neurons. Peripheral
CGRP-LI fibers terminate in lamina I, III and V of spinal
cord [80] and CGRP-containing DRG neurons innervate
joints [81]. Thus, CGRP and its receptors are widely dis-
tributed in peripheral and central pain pathways.
In animals CGRP can be released from peripheral and
central nerve endings upon noxious pain mechanical
stimulation of the skin [82–85]. In rats, the major part
of circulating CGRP is released from perivascular nerve
terminals [86, 87]. Acute and chronic nociception leads
to altered release of CGRP from sensory nerve endings
and central terminals into the dorsal horn of the spinal
cord [88–91]. In rats, CGRP applied spinally causes fa-
cilitation of central excitability and central sensitization
[92, 93]. Kessler et al. [94] demonstrated reduced mech-
anical allodynia in an animal model of OA following ad-
ministration of an intrathecal CGRP receptor antagonist
[94]. Animal in vitro studies reported direct activation of
nociceptors by CGRP [95, 96]. CGRP injected into
mouse hind paw skin produced mechanical allodynia
[97]. In humans, however, a direct activation of nocicep-
tive fibers is unlikely. CGRP injected intradermally or
intramuscularly did not produce pain [98].
CGRP is also found in free nerve endings in skin and
synovium) and perivascular afferents in different struc-
tures in both humans and animals [99–101]. The release
of CGRP from these fibers causes vasodilation suggesting
a role in neurogenic inflammation [98, 101, 102]. The
question is whether CGRP exerts either pro- or anti-
inflammatory/nociceptive effects. It is possible that CGRP
release reflects the response of the nocifensor system to
injury and inflammation to evoke protective vasodilata-
tion. Deficiency of alpha CGRP (αCGRP knockout mice)
was associated with enhanced inflammatory responses in
the hippocampus and hypothalamus and reduced the sur-
vival rate compared to wild-type mice in septic shock con-
dition [103]. However, αCGRP knockout mice displayed
lower pain sensitivity to heat stimulation faster accumula-
tion of c-Fos compared to wild-type animals after incision
and complete Freund’s adjuvant injection [104]. In ani-
mals, sustained CGRP release may induce peripheral
sensitization [105] likely due to release of inflammatory
mediators (bradykinin, prostaglandins, etc.) from nerve
endings and cells of immune system [106–108].
Inflammatory diseases of the joints tendons and discs
may be associated with elevated levels of CGRP
(Additional files 1 and 2: Tables S1 and S2). These data
suggest that abnormal release of CGRP could be a
marker of sensory afferent activation. Comparing CGRP
changes in different tissue materials (i.e. blood, syno-
vium, skin, CSF, ligament tissue, mucosa, etc.), it seems
that elevated CGRP is more frequently found in blood,
synovium and skin. Bullock et al. [109] suggested that
CGRP release during joint degeneration in osteoarthritis
might play an important role in the peripheral
sensitization and proposed possible analgesic effect of
CGRP antagonists in this condition. CGRP stimulates
proliferation and migration of human endothelial cells
[110], causing angiogenesis with the co-localized CGRP-
containing perivascular nerve fibers. Intra-articular
growth of CGRP-containing perivascular nociceptors
have been reported in patients with osteoarthritis. It has
further been shown that nociceptive nerve fibers innerv-
ating joints are sensitized in these patients [111] contrib-
uting to the experience of pain. Immunohistochemistry
of forearm skin biopsies in patients with congenital in-
sensitivity to pain (CIP) showed reduced amount of
CGRP compared to controls [112]. Thus, measurement
of CGRP may be regarded a marker of sensory afferent
activation in the respective tissue during a pain condi-
tion [113]. This indicates that CGRP not only contrib-
utes to proliferation of CGRP-containing nociceptors,
but could sensitize these nociceptors via neurogenic in-
flammation in humans. Whether CGRP causes pain per
se can be examined by application of exogenous CGRP.
Interestingly, dose-dependent angiogenesis after intra-
articular CGRP injection in the rat knee can be blocked
by the CGRP receptor antagonist, BIBN4096BS [114].
One way of exploring this hypothesis would be to study
CGRP levels in humans after exposure to painful stimuli.
In healthy volunteers, intradermal capsaicin injections
produced a steady increase of CGRP levels in the first
sampling period, but failed to reach significance in the
second session [45]. The latter could be explained by
capsaicin-induced desensitization of neuropeptide re-
lease from primary afferents [115]. Another study dem-
onstrated that capsaicin-induced vasodilation in the
human skin was mainly mediated by CGRP and not by
other substances with vasodilator properties including
prostaglandins, nitric oxide, or substance P [116]. Only
few studies have investigated the effect of CGRP antag-
onist after intradermal capsaicin injections [66, 117].
Chi-Chung Li et al. [117] reported that CGRP antagonist
MK-3207 inhibited capsaicin-induced vasodilation in
skin. Sinclair et al. [118] demonstrated reduced increase
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in dermal blood flow after topical capsaicin application
in the forearm of healthy volunteers who were pre-
treated with CGRP antagonist (telcagepant). The degree
of inhibition in capsaicin-induced dermal blood flow was
shown to be increased with higher LY2951742, CGRP
monoclonal antibody, plasma concentrations suggesting
dose–response relationship [119].
While increased CGRP levels in the affected tissue and
synovial material indicate ingrowth of pain sensitive nerve
fibers in the tissue it is unclear why CGRP level increases
in blood and skin. CGRP is synthesized in central and per-
ipheral neurons [120]. Two studies investigated CGRP
levels in the cerebrospinal fluid during pain and found 1)
no difference in cancer pain patients compared to controls
[35], and 2) low CGRP levels in osteoarthrosis patients
[25]. In contrast, biochemical studies in osteoarthrosis pa-
tients reported a positive association between pain and
CGRP levels in blood [17, 18], synovial material [20–22],
and skin [19]. Dermal electrical current stimulation in
humans caused increased CGRP in blood [48]. However, a
recent study randomized, double-blind, placebo and
active-controlled study in patients with osteoarthritis knee
pain did not demonstrate efficacy of LY2951742, mono-
clonal antibody to CGRP against placebo and the trial was
terminated [68]. However, the study was only done in pa-
tients with mild and moderate symptoms. It is possible
that patients with severe osteoarthritis involving other
joints may respond differently. Other factors that may
confound the results include the long duration of the dis-
ease (not reported in abstract), which can indicate pres-
ence of central sensitization and level of activity of
patients that may worsen symptoms including pain. No
studies to date have investigated the efficacy of monoclo-
nal antibodies against CGRP receptor in patients with
osteoarthritis knee pain.
Further studies addressing these issues are warranted.
Conclusions
The present review suggests that CGRP may play a role
in pain transmission in somatic pain conditions such as
joint and muscular chronic pain. CGRP might have a
pro-inflammatory role in peripheral nervous system by
leading to release of pro-nociceptive substances and by
facilitating central nociceptive transmission and contrib-
uting to central sensitization. However, the exact mecha-
nisms and involvement of CGRP in nociceptive
processing are not fully clarified. Understanding these
mechanisms may lead to the potential development of
new pharmacotherapies targeting CGRP and its recep-
tors. Efficacy and safety of the CGRP antagonists and
antibodies has already been established in migraine and
this paves the way for more clinical trials in non-
headache pain conditions.
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